Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05892718
Other study ID # HCB101-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 2, 2023
Est. completion date November 15, 2025

Study information

Verified date April 2024
Source FBD Biologics Limited
Contact FBD Clinical
Phone +886-2-27921366
Email HCB101-101@hanchorbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.


Description:

This is an open-label, multi-center, dose-escalation, Phase 1 study. This study is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity, and identification of maximum tolerated dose (MTD) of HCB101 intravenous injection in adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. Eligible subjects must have failed standard therapies, been intolerable, or been considered medically inappropriate by the investigator. Subjects will be treated until unacceptable AEs, radiographic or clinical documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study, whichever occurs first.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date November 15, 2025
Est. primary completion date May 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able to understand and willing to sign the ICF. 2. Male and female subjects of =18 years of age. 3. Histologically/cytologically confirmed, locally advanced solid tumor: subjects with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy. 4. For subjects with advanced solid tumor - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline. 5. For subjects with non-Hodgkin lymphoma - must have non-Hodgkin lymphoma that is measurable or assessable for response per Lugano Classification (with 2016 refinement). 6. Must have ECOG performance status of 0 to 2 at Screening. 7. Able to provide tumor tissue samples. 8. Have life expectancy of =12 weeks. Exclusion Criteria: 1. With known history of hypersensitivity to any components of HCB101. 2. Known active or untreated CNS metastases and/or carcinomatous meningitis. 3. Have undergone a major surgery or radical radiotherapy or palliative radiotherapy or have used a radioactive drug that is not completed at least 2 weeks prior to the first dose of HCB101. 4. Clinically significant cardiovascular condition. 5. Any previous treatment-related toxicities which have not recovered to = Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia. 6. With known inherited or acquired bleeding disorder or bleeding diathesis. . 7. Have RBC transfusion within 4 weeks prior to Screening. 8. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months. 9. Any investigational or approved systemic cancer therapy. 10. Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin = 81 mg/QD. 11. Have used herbal medication within 14 days prior to the first dose of HCB101. 12. Have received any treatment targeting the CD47 or SIRPa pathway. 13. Have other malignancies requiring treatment within 2 years prior to the first dose of HCB101. 14. Participation in another clinical study with an investigational product administered in the last 14 days prior to receiving the first dose of HCB101. 15. An investigational device used within 28 days prior to the first dose of HCB101. 16. Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis. 17. Known to have a history of alcoholism or drug abuse.

Study Design


Intervention

Drug:
HCB101
HCB101 administered via. intravenous (IV) infusion.

Locations

Country Name City State
Taiwan Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare New Taipei City
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
United States UT Southwestern Medical Center Dallas Texas
United States Greenville Hospital System University Medical Center (ITOR) Greenville South Carolina
United States Carolina BioOncology Huntersville North Carolina
United States Hematology-Oncology Associates of the Treasure Coast Port Saint Lucie Florida

Sponsors (1)

Lead Sponsor Collaborator
FBD Biologics Limited

Countries where clinical trial is conducted

United States,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Other CD47 receptor occupancy on circulating red blood cells (RBCs) CD47 receptor occupancy on circulating red blood cells (RBCs) will be measured as an indication of target engagement. 12 months
Other Concentration of potential PD biomarkers in participants will be assess. Changes in macrophage function related cytokines will be assess after HCB101 treatment. 12 months
Other ctDNA detection ctDNA detection in participants using next-generation sequencing (NGS ). 12 months
Primary Number/incidence and percentage of subjects with adverse events, including ADA. To evaluate the safety and tolerability of HCB101 12 months
Primary Number of subjects with MTD of HCB101 To evaluate the safety and tolerability of HCB101 12 months
Secondary Overall Rate Response (ORR) ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR) 12 months
Secondary Duration of Response (DoR) DOR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD) 12 months
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of participants who have a partial response (PR), critical response (CR), or disease stable (SD) 12 months
Secondary Progression-Free Survival (PFS) Defined as the duration from the start of treatment until tumor progression or death of any cause. 12 months
Secondary Peak Plasma Concentration (Cmax) of HCB101 Peak Plasma Concentration (Cmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. 12 months
Secondary Area under the plasma concentration versus time curve (AUC) of HCB101 Area under the plasma concentration versus time curve (AUC) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. 12 months
Secondary Time to maximum drug concentration in plasma (Tmax) of HCB101 Time to maximum drug concentration in plasma (Tmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. 12 months
Secondary Terminal elimination half-life (t1/2) of HCB101 Terminal elimination half-life (t1/2) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1